Roche’s (ROG: SIX) shares were down 1.5% to 390.80 francs in early trading, as the Swiss pharma giant released sales figures for the first nine months of 2021.
Group sales increased by 8% (6% in francs) to 46.7 billion francs ($50.6 billion) in the reporting period, boosted by a strong performance in its diagnostics business. Roche does not release earnings figures on a quarterly basis.
Pharmaceuticals Division sales remained stable at 33.4 billion francs. Since summer there have been signs of recovery from the COVID-19 pandemic and the biosimilar impact is slowing down as expected (Pharma sales: -9% in the first quarter, +4% in the second quarter and +5% in the third quarter).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze